Does BIOVENTUS INC. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores BIOVENTUS INC. (BVS) 56.4 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 97, returns on capital 7, balance-sheet safety 67, capital discipline 58.

Is BVS stock trading below its intrinsic value?

Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $3.25 per share versus a recent price of $12.06 — 272% above value. This is an educational estimate computed from primary SEC filings, not investment advice.

How has BVS's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 56.4 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

BIOVENTUS INC.

BVS · Healthcare · $831.1M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power97

Median gross margin 68.3% over 7y, very stable.

Returns on capital7

Median ROIC -2.7%, above the 9% hurdle in 20% of years.

Balance-sheet safety67

Net debt/EBITDA 2.4x, no material interest expense disclosed.

Capital discipline58

Owner earnings +11.6%/yr, share count growing (dilution).

Margin of safety

Above valueOn sale

272% above value

Owner earnings (normalized): $12.4M
Est. intrinsic value / share: $3.25
Recent price: $12.06
Discount to value: 272% above value

Conservative model: 9% discount rate, 4% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for BVS yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale56.4 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — BVS has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#89 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#87TRMB TRIMBLE INC.56.8 out of 100, Shallow moatShallow moat
#88TMO THERMO FISHER SCIENTIFIC INC.56.7 out of 100, Shallow moatShallow moat
#90IMAX IMAX Corporation56.3 out of 100, Shallow moatShallow moat
#91ACAD ACADIA PHARMACEUTICALS INC56.2 out of 100, Shallow moatShallow moat

Compare BVS with its nearest peers →All Healthcare companies on the Index →

Common questions about BVS

Does BIOVENTUS INC. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores BIOVENTUS INC. (BVS) 56.4 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 97, returns on capital 7, balance-sheet safety 67, capital discipline 58.
Is BVS stock trading below its intrinsic value?: Against a deliberately conservative owner-earnings model (9% discount rate, 4% assumed growth, capped at 4%), estimated intrinsic value is $3.25 per share versus a recent price of $12.06 — 272% above value. This is an educational estimate computed from primary SEC filings, not investment advice.
How has BVS's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 56.4 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows BVS’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/BVS"
  width="340" height="150" style="border:0"
  title="BVS Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell BVS. See the disclaimer.